Printer Friendly Version
David Abramowitz is a Partner in Locke Lord's IP Pharmaceutical and Biotechnology and IP Litigation practice groups. David's practice primarily focuses on complex patent litigation brought under the Hatch-Waxman amendments to the Federal Food, Drug, and Cosmetic Act and the Biologics Price, Competition, and Innovation Act, where he has significant experience representing and counseling generic pharmaceutical and biotechnology companies in federal intellectual property litigation. He also has extensive experience litigating other intellectual property disputes concerning patents, copyrights, trademarks, rights of publicity, trade secrets, unfair competition, and defamation. Before attending law school, he worked in academic laboratories where he gained research experience in the areas of organic chemistry, biochemistry, cell biology, material science, polymer science, and nanotechnology.
News, Events, Notable Matters, and More
Showing Results for
Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.